Cargando…

Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of glucose-lowering agents which have changed the landscape of diabetes therapy, due to their remarkable cardiorenal protective properties. The attack of severe acute respiratory syndrome coronavirus 2 on the heart and kidneys share...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koufakis, Theocharis, Pavlidis, Antonis N., Metallidis, Symeon, Kotsa, Kalliopi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942520/ https://www.ncbi.nlm.nih.gov/pubmed/33751323 http://dx.doi.org/10.1007/s11096-021-01256-9

Ejemplares similares

COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Looking deeper into the findings of DARE-19: Failure or an open door to future success?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

The role of sexual dimorphism in susceptibility to SARS-CoV-2 infection, disease severity, and mortality: facts, controversies and future perspectives
por: Pegiou, Stavroula, et al.
Publicado: (2021)

Antiatherosclerotic Effects of Sodium-Glucose Cotransporter 2 Inhibitors: An Underrecognized Piece of the Big Puzzle?
por: Koufakis, Theocharis, et al.
Publicado: (2022)

From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Changes in the Global Epidemiology of Type 1 Diabetes in an Evolving Landscape of Environmental Factors: Causes, Challenges, and Opportunities
por: Ogrotis, Ioannis, et al.
Publicado: (2023)

Epidemiological, Pathophysiological, and Clinical Considerations on the Interplay between Thyroid Disorders and Type 2 Diabetes Mellitus
por: Grigoriadis, Gregory, et al.
Publicado: (2023)

Changes in dietary intake of aspartic acid during and after intermittent fasting correlate with an improvement in fasting glucose in overweight individuals
por: Karras, Spyridon N., et al.
Publicado: (2023)

Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
por: Vasdeki, Dimitra, et al.
Publicado: (2022)

The importance of sleep quality, quantity, and chronotype in the management of diabetes: Is it time to wake up?
por: Koufakis, Theocharis, et al.
Publicado: (2022)

How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
por: Arvanitakis, Konstantinos, et al.
Publicado: (2022)

Deconvoluting the Biological Roles of Vitamin D-Binding Protein During Pregnancy: A Both Clinical and Theoretical Challenge
por: Karras, Spyridon N., et al.
Publicado: (2018)

Managing Diabetes in the Era of Financial Crisis: Need to Look Beyond the Obvious
por: Koufakis, Theocharis, et al.
Publicado: (2018)

Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun
por: Karras, Spyridon N, et al.
Publicado: (2019)

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
por: Rentzeperi, Elpiniki, et al.
Publicado: (2022)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
por: Arvanitakis, Konstantinos, et al.
Publicado: (2023)

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)

Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study
por: Kolokas, Konstantinos, et al.
Publicado: (2020)

The Relationship between Primary Hyperparathyroidism and Thrombotic Events: Report of Three Cases and a Review of Potential Mechanisms
por: Koufakis, Theocharis, et al.
Publicado: (2018)

Infectious mononucleosis skin rash without previous antibiotic use
por: Koufakis, Theocharis, et al.
Publicado: (2015)

Effects of Christian Orthodox Fasting Versus Time-Restricted Eating on Plasma Irisin Concentrations Among Overweight Metabolically Healthy Individuals
por: Karras, Spyridon N., et al.
Publicado: (2021)

At the Crossroads of Inflammation and Tumorigenesis
por: Cordon-Cardo, Carlos, et al.
Publicado: (1999)

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Another Report of Acalculous Cholecystitis in a Greek Patient with Infectious Mononucleosis: A Matter of Luck or Genetic Predisposition?
por: Koufakis, Theocharis, et al.
Publicado: (2016)

The epitranscriptome: At the crossroad of cancer prognosis
por: Di Fazio, Pietro
Publicado: (2021)

Interventional electrophysiology at a crossroads
por: Hauser, Robert G., et al.
Publicado: (2022)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

First Report of Diabetes Phenotype due to a Loss-of-Function ABCC8 Mutation Previously Known to Cause Congenital Hyperinsulinism
por: Koufakis, Theocharis, et al.
Publicado: (2019)

CCL2 at the crossroad of cancer metastasis
por: Eferl, Robert
Publicado: (2013)

Sodium–glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties
por: Li, Hung‐Yuan
Publicado: (2020)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

ARF1 at the crossroads of podosome construction and function
por: Genot, Elisabeth
Publicado: (2017)

At the crossroads of religion and palliative care in patients with dementia
por: Quinn, Kieran L., et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
por: Yurista, Salva R., et al.
Publicado: (2020)

The Road Not So Travelled: Should Measurement of Vitamin D Epimers during Pregnancy Affect Our Clinical Decisions?
por: Karras, Spyridon N., et al.
Publicado: (2017)

Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_op220707sie1hgkat23k8ge5g2